Clinical trials: Non-small Cell Lung Cancer NSCLC, open to volunteers
Lung Cancer Non-small Cell, Colorectal Cancer
Multimodal Liquid-Biopsy Omics Biomarkers of Treatment Response in Breast Cancer
This single-center cohort study integrates humoral immune response profiling (Phage ImmunoPrecipitation Sequencing, PhIP-seq) with circulating cell-free DNA (cfDNA) genomic and epigenomic features, exosome transcriptomics, and…
- Conditions
- Lung Cancer Non-small Cell, Colorectal Cancer, Stomach Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07880106
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Leptomeningeal Metastasis From Lung Cancer
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
Brief Summary (English) The goal of this clinical trial is to learn if a risk-adaptive consolidation therapy, guided by cerebrospinal fluid (CSF) circulating tumor DNA (ctDNA) clearance kinetics after induction intrathecal…
- Trial name
- NCT07751536
- Testing
- proton craniospinal irradiation, Intrathecal pemetrexed
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- Shuanghu Yuan
Surgical Procedure, Unspecified, Non Small Cell Lung Cancer
Fissios© and Postoperative Complications (FPoC Trial)
Respiratory physiotherapy as part of a pre-operative physical training program may reduce the risk of developing post-operative complications, improving post-operative results and optimizing physical conditions in patients with a…
- Conditions
- Surgical Procedure, Unspecified, Non Small Cell Lung Cancer, Surgery Scheduled, Thoracic Surgery
- Trial name
- FPoC (NCT06732193)
- Testing
- On-site respiratory physiotherapy, Fissios App
- Where
- Spain
- Volunteers
- 560 people
- Sponsor
- Carlos Alfredo Fraile Olivero, MD, PhD.
NSCLC Stage IV
Primary Tumor Resection With EGFR TKI for Stage IV NSCLC
Our project is going to enroll patients with stage IV NSCLC with EGFR mutation and evaluate whether primary tumor resection after receiving the afatinib can prolong survival.
- Trial name
- NCT05215548
- Testing
- therapeutic thoracic surgery, Afatinib
- Where
- 2 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Lung Cancer - Non Small Cell, Lung Cancer (NSCLC)
Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients
Early palliative care has been shown to improve the survival of advanced lung cancer patients. However, most of the clinical studies were performed in the era when systemic treatment options for this disease were limited.
- Trial name
- NCT06786468
- Testing
- Early palliative care integration, Standard systemic treatment for advanced lung cancer
- Where
- Thailand
- Volunteers
- 104 people
- Sponsor
- Mahidol University
Non-Small Cell Lung Cancer
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy…
- Trial name
- NCT06885840
- Testing
- MCLA-129
- Where
- 20 sites in China
- Volunteers
- 100 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer With EGFR Mutation
Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
This open-label randomized clinical trial aims to evaluate the glutamine plus Lactobacillus reuteri supplementation effect in a standard-of-care diet in EGFR mutant patients with advanced non-small cell lung cancer (NSCLC) under…
- Trial name
- NCT05852990
- Testing
- Glutamine plus L. reuteri
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Instituto Nacional de Cancerologia de Mexico
EGFR-mutant Non-small Cell Lung Cancer, SBRT
Consolidative Stereotactic Radiotherapy for Oligo-Residual Advanced EGFR-Mutant NSCLC After First-Line Third-Generation EGFR-TKI Plus Chemotherapy
This national multicenter, randomized controlled clinical trial evaluates the safety and efficacy of consolidative stereotactic radiotherapy in patients with advanced EGFR-mutant non-small cell lung cancer who have oligo-residual…
- Conditions
- EGFR-mutant Non-small Cell Lung Cancer, SBRT, NSCLC (Advanced Non-small Cell Lung Cancer)
- Trial name
- NCT07822984
- Testing
- Third-generation EGFR tyrosine kinase inhibitor, Platinum plus pemetrexed chemotherapy, Pemetrexed maintenance therapy
- Volunteers
- 374 people
- Sponsor
- Fudan University
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is a single arm study to access the anti-tumor efficacy and safety of Andamertinib plus Anlotinib in patients with locally advanced or metastatic non-small cell lung cancer previously treated with third-generation…
- Trial name
- NCT07780578
- Testing
- Andamertinib, Anlotinib
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Fudan University
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Sarcoma, Synovial, Sarcoma,Soft Tissue
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
A Phase I/II Dose Escalation, Safety and Efficacy Study of HBI 0201-ESO TCRT (anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes) Given by Infusion to Patients with NY-ESO-1 -Expressing Metastatic Cancers
- Conditions
- Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV, Triple Negative Breast Cancer
- Trial name
- NCT05296564
- Testing
- CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- Hadassah Medical Organization
NSCLC, Tislelizumab
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
In clinical practice, some patients cannot tolerate concurrent chemoradiotherapy. The purpose of this study is to observe the efficacy and safety of platinum-based doublet chemotherapy followed by hypofractionated radiotherapy…
- Conditions
- NSCLC, Tislelizumab, Chemotherapy, Hypofractionated Radiotherapy
- Trial name
- NCT07198217
- Testing
- SBRT combined with Tislelizumab followed by Tislelizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zibo Municipal Hospital
Locally Advanced/Recurrent or Distant Metastasized Non-small Cell Lung Cancer With MET Overexpression
A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel（Albumin Bound）Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer
This study consists of Stage 1 (including dose escalation and dose expansion) and Stage 2 (randomized controlled study). The main purpose of Stage 1 is to preliminarily evaluate the safety and tolerability of the combination of…
- Trial name
- NCT06525350
- Testing
- Glumetinib tablets, HB1801 (docetaxel, albumin-bound）, Docetaxel
- Volunteers
- 256 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 14 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Non-Small Cell Lung Cancer
IMP3-saRNA Vaccine in Advanced NSCLC
This is an open-label, single-arm, non-randomized, single-center, prospective phase 1 clinical trial. The study will evaluate the safety, tolerability, and preliminary antitumor activity of IMP3-saRNA (YMN-136) vaccine in…
- Trial name
- NCT07561723
- Testing
- IMP3-saRNA (YMN-136) Vaccine
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Stage III Non-small Cell Lung Cancer
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial
For stage III non-small cell lung cancer (NSCLC), neoadjuvant chemotherapy plus PD-1 antibody is recommended. However, most patients could not achieve complete pathological response (CPR).
- Trial name
- NCT05891080
- Testing
- Toripalimab, JS004, Pemetrexed
- Volunteers
- 124 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm
Phase II Trial of Lung Chemoemobolization
This phase II trial evaluates how well transarterial chemoembolization (TACE) works for treating patients with non-small cell lung cancer or lung metastases.
- Conditions
- Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm, Lung Metastases From Any Primary
- Trial name
- NCT05672108
- Testing
- Computed Tomography, Ethiodized Oil, Mitomycin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Advanced and Metastatic NSCLC
Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer
The goal of this clinical trial is to learn if diphenhydramine can improve the effectiveness and decrease the toxicity for the treatment of advanced and metastatic Non-small cell lung cancer (NSCLC) with PD1 inhibitor plus…
- Trial name
- NCT06704620
- Testing
- Diphenhydramine, Tislelizumab, Pemetrexed
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Lung Cancer, Non-squamous, Non-small Cell
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab
This study is open to adults with a type of lung cancer called HER2-mutant non-squamous non-small cell lung cancer (NSCLC) that is advanced or has spread.
- Trial name
- NCT07486817
- Testing
- Zongertinib, Cisplatin, Carboplatin
- Where
- 17 sites in Australia, China and 5 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Squamous Non-small Cell Lung Cancer
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC).
- Trial name
- INTerpath-13 (NCT07221474)
- Testing
- Intismeran Autogene, Pembrolizumab, Carboplatin
- Where
- 55 sites in United States, Argentina and 9 more
- Volunteers
- 180 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.